Loading
NASDAQHealthcareBiotechnology
Latest quote
$31.81
−$0.11 · -0.34%
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
Previous close
$31.81
−$0.11 · -0.34%
Regular session · ET · Market data may be delayed.
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
Day range
Current $31.81
52-week range
Current $31.81
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
2
Overpriced
Sentiment
64
Bullish
Risk
42
Elevated Risk
Momentum
64
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
Day range
Current $31.81
52-week range
Current $31.81
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI63.84M0.00%2.3T USD0.03%$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI55.11M0.56%9.87B USD0.35%$153.77+3.00%
iShares Russell 2000 ETFIWM49.6M0.06%78.27B USD0.19%$278.94+0.49%
Vanguard Morningstar Small-Cap ETFVB46.06M0.02%185.3B USD0.03%$289.48+0.64%
Vanguard Morningstar Small-Cap Growth ETFVBK26.39M0.06%44.7B USD0.05%$344.74+1.22%
Vanguard Extended Market ETFVXF23.28M0.02%95.4B USD0.05%$235+0.80%
iShares Biotechnology ETFIBB14.41M0.14%10.28B USD0.44%$206.49+3.00%
Dimensional - US Small Cap ETFDFAS14.31M0.04%33.87B USD0.31%$78.35+0.32%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBDimensional - US Small Cap ETFDFASAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
